Brincidofovir - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for brincidofovir and what is the scope of freedom to operate?
Brincidofovir
is the generic ingredient in one branded drug marketed by Emergent Biodefense and is included in two NDAs. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.Brincidofovir has forty-seven patent family members in fifteen countries.
Two suppliers are listed for this compound.
Summary for brincidofovir
| International Patents: | 47 |
| US Patents: | 5 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 32 |
| Clinical Trials: | 20 |
| Patent Applications: | 436 |
| What excipients (inactive ingredients) are in brincidofovir? | brincidofovir excipients list |
| DailyMed Link: | brincidofovir at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for brincidofovir
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for brincidofovir
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Emergent BioSolutions | Phase 1 |
| SymBio Pharmaceuticals | Phase 2 |
| SymBio Pharmaceuticals | Phase 1 |
Anatomical Therapeutic Chemical (ATC) Classes for brincidofovir
US Patents and Regulatory Information for brincidofovir
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Emergent Biodefense | TEMBEXA | brincidofovir | TABLET;ORAL | 214461-001 | Jun 4, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Emergent Biodefense | TEMBEXA | brincidofovir | TABLET;ORAL | 214461-001 | Jun 4, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Emergent Biodefense | TEMBEXA | brincidofovir | TABLET;ORAL | 214461-001 | Jun 4, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Emergent Biodefense | TEMBEXA | brincidofovir | SUSPENSION;ORAL | 214460-001 | Jun 4, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for brincidofovir
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Israel | 245576 | צורות מורפיות של הקסאדציקלוקסיפרופיל-פוספונאט אסטרים (Morphic forms of hexadecyloxypropyl-phosphonate esters) | ⤷ Sign Up |
| Russian Federation | 2015141024 | ПРОИЗВОДНЫЕ ЭФИРОВ ФОСФОНОВЫХ КИСЛОТ И СПОСОБЫ ИХ СИНТЕЗА | ⤷ Sign Up |
| South Korea | 20160078500 | 헥사데실옥시프로필-포스포네이트 에스테르의 형체 형태 (MORPHIC FORMS OF HEXADECYLOXYPROPYL-PHOSPHONATE ESTERS) | ⤷ Sign Up |
| South Korea | 20170143009 | 헥사데실옥시프로필-포스포네이트 에스테르의 형체 형태 (- MORPHIC FORMS OF HEXADECYLOXYPROPYL-PHOSPHONATE ESTERS) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
